Upcoming Events
Recent courses
What anti-obesity medications are in development?
|
Incretin medications, like semaglutide and tirzepatide, suppress appetite and delay gastric emptying, facilitating weight loss and begging the question of the need for concurrent behavior change th
|
In this co-presentation, we will explore the fascinating link between body composition changes, the use of anti-obesity medications, and the innovative approach of clinician-led obesity care.
|
Pages
The material presented by the Obesity Medicine Association (OMA) is for educational purposes only. Opinions expressed do not necessarily reflect those of OMA. The material is not intended to represent the only or necessarily best method or procedure appropriate for the medical situations discussed. Instead, it is intended to present an approach, view, statement, or opinion of the faculty that may be helpful to others who face similar situations. The individual is responsible for becoming familiar with laws and prescribing limitations within his or her own state before practicing various therapies. OMA also presents a forum for its members to be exposed to various products and services. It is the responsibility of each attendee or member to do due diligence, including reviewing literature, lectures, and background information.
OMA disclaims any and all liability for injury or other damages resulting to any individual viewing pages on obesitymedicine.org or academy.obesitymedicine.org and for all claims that may arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by physician or any other person.